Strategic application domain: Biotech - Pharma
Application market: Neurology & Mental Health Disorders
Type of activity: Therapeutics, Pharma or Biotech
Our primary hypothesis is that occurrence of a seizure-induced fatal apnea in Dravet syndrome (DS) results from development of progressive epilepsy-related vulnerability to central respiratory dysfunction linked to brainstem serotonin (5HT) dysfunction.
In the seroDRAVET project, we will: (i) analyze the temporal relationship between evolution of epilepsy and alteration of respiratory function in a model of DS, (ii) determine, both in rodents and in patients, the relation between alterations of the brainstem 5HT pathway and respiratory dysfunction, and (iii) validate that modulation of activity of 5HT neurons modifies the risk of seizure-related fatal apnea in DS.
ANR
ANR Générique
PRC 2021
2021
national project
On going
Duration: 48 months
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.